PharmNovo signs agreement with Worldwide Clinical Trials for phase IIa study of PN6047 in neuropathic pain
PharmNovo, a Swedish pharmaceutical company developing neuropathic pain treatments, announces its collaboration with Worldwide Clinical Trials, a full-service contract research organisation (CRO), to conduct the phase IIa study of PN6047.The study is planned to start in 2024.In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep.